Enterprise Value
155.5M
Cash
117.7M
Avg Qtr Burn
-11.81M
Short % of Float
0.56%
Insider Ownership
20.86%
Institutional Own.
56.40%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Soticlestat (OV935) Details Dravet syndrome, Rare diseases, Rare genetic disease | Phase 3 Update | |
OV329 (GABA-AT inhibitor) Details Epilepsy | Phase 1 Data readout | |
OV101 (δ-selective GABAA receptor agonist) (gaboxadol) Details Genetic disorder, Rare genetic disease, Angelman Syndrome | Failed Discontinued | |
OV101 (gaboxadol) Details Rare genetic disease, Fragile X syndrome | Failed Discontinued | |
OV935 (CH24H Inhibitor) Details Rare diseases, Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder, Rare genetic disease | Failed Discontinued |